<DOC>
	<DOCNO>NCT00905983</DOCNO>
	<brief_summary>Lung cancer one common malignancy worldwide lead cause cancer-related death Western country . Standard treatment patient good performance status ( PS ) stage IIIB/IV NSCLC currently include two-drug platinum-based chemotherapy regimen , optimum treatment elderly patient less well-defined due platinum related toxicity . Several drug novel mechanism action significant activity NSCLC develop ; include docetaxel gemcitabine also active patient previously treat cisplatin-based regimen favorable toxicity profile . The favorable toxicity profile docetaxel gemcitabine support use first-line chemotherapy , especially patient severe comorbidities elderly patient . To improve therapeutic index combination , investigator perform study biweekly gemcitabine docetaxel elderly patient .</brief_summary>
	<brief_title>Biweekly Gemcitabine Docetaxel First Line Treatment Advanced Disease Elderly Non-Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance NSCLC . Stage III pleural effusion stage IV . Patients 70 year old . Patients 1 &gt; ECOG PS =1 . Patients must least one measurable lesion , previously irradiate . Life expectancy least 12 week . Adequate organ function accord follow criterion : Bone marrow : ANC &gt; = 2.0x10 ( 9 ) cells/L ; Platelet count &gt; = 100x10 ( 9 ) cells/L ; Leukocyte count &gt; = 4000x10 ( 6 ) /L ; Hemoglobin &gt; = 10 g/dL . Liver function : Bilirubin &lt; = 1.5 X ULN ; Alkaline phosphatase &lt; = 5 x ULN ; AST ALT &lt; = 1.5 x ULN . Renal function : serum creatinine &lt; = 2mg/dL . Prior systemic chemotherapy advance disease . Patients symptomatic brain metastasis . No measurable bone metastasis malignant pleural effusion measurable lesion . History prior malignancy , except curatively treat situ carcinoma cervix cancer curatively treat evidence disease least five year . History hypersensitivity reaction study drug . Concurrent treatment experimental drug . Current peripheral neuropathy NCI grade 2 . Participation clinical trial within 30 day study entry . Major surgery , open biopsy traumatic lesion 28 day study start .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Carcinoma , Non-Small-Cell</keyword>
	<keyword>Elderly patient</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>